The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Insights into a MAIC comparing IberDd against daratumumab plus IMiD containing regimens in myeloma
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the results of a matching-adjusted indirect comparison (MAIC) analysis comparing iberdomide in combination with daratumumab and dexamethasone (IberDd) to daratumumab and IMiD-containing regimens in multiple myeloma, highlighting that iberdomide demonstrates a significantly higher measurable residual disease (MRD) negativity rate and a favorable safety profile, despite the comparisons not being head-to-head. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
